trial

Navigated αTMS in Treatment-resistant Schizophrenia

NCTId NCT01941251
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Active Not Recruiting
Enrollment 50 (actual)
Sponsored by Niuvanniemi Hospital
Primary completion 2015-12-21
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Active Not Recruiting
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2013-03-21
Primary completion
2015-12-21
Eligibility
MALE · 18 Years · 64 Years

Interventions & indications

Drugs
navigated Transcranial Magnetic Stimulation

Sponsors

Niuvanniemi HospitalLead Sponsor

Investigators

1
Heli Tuppurainen, MD, PhDPrincipal Investigator

Sites

1 total
Kuopio, Finland

Facts & assertions

4 sourced
Enrollment
50
Phase
NA
Primary Completion Date
2015-12-21
Status
ACTIVE_NOT_RECRUITING
relationships
The graph out of here
drug
navigated Transcranial Magnetic Stimulation
drug
lead_sponsor
Niuvanniemi Hospital
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Heli Tuppurainen, MD, PhD
person